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Background: Microglial activation is a pathological feature common to both Alzheimer’s and Parkinson’s diseases
(AD and PD). The classical activation involves release of pro-inflammatory cytokines and reactive oxygen species.
This is necessary for maintenance of tissue homeostasis and host defense, but can cause bystander damage when
the activation is sustained and uncontrolled. In recent years the heterogeneous nature of microglial activation states
in neurodegenerative diseases has become clear and the focus has shifted to alternative activation states that
promote tissue maintenance and repair. We studied the distribution of CD163, a membrane-bound scavenger
receptor found on perivascular macrophages. CD163 has an immunoregulatory function, and has been found in the
parenchyma in other inflammatory diseases e.g. HIV-encephalitis and multiple sclerosis. In this study, we used
immunohistochemistry to compare CD163 immunoreactivity in 31 AD cases, 27 PD cases, and 16 control cases.
Associations of microglia with pathological hallmarks of AD and PD were investigated using double
immunofluorescence.
Results: Parenchymal microglia were found to be immunoreactive for CD163 in all of the AD cases, and to a lesser
extent in PD cases. There was prominent staining of CD163 immunoreactive microglia in the frontal and occipital
cortices of AD cases, and in the brainstem of PD cases. Many of them were associated with Aß plaques in both
diseases, and double staining with CD68 demonstrates their phagocytic capability. Leakage of fibrinogen was observed
around compromised blood vessels, raising the possibility these microglia might have originated from the periphery.
Conclusions: Increase in microglia’s CD163 immunoreactivity was more significant in AD than PD, and association of
CD163 immunoreactive microglia with Aβ plaques indicate microglia’s attraction towards extracellular protein
pathology, i.e. extracellular aggregates of Aβ as compared to intracellular Lewy Bodies in PD. Double staining with
CD163 and CD68 might point towards their natural inclination to phagocytose plaques. Fibrinogen leakage and
compromise of the blood brain barrier raise the possibility that these are not resident microglia, but systemic
macrophages infiltrating the brain.
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Microglia, immune cells specific to the brain, have been
the focus of considerable interest by virtue of their asso-
ciation with the pathological hallmarks of Alzheimer’s
Disease (AD), namely senile plaques consisting of mostly
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unless otherwise stated.composed of hyperphosphorylated tau. Activated micro-
glia are also seen in the substantia nigra (SN) and the
striatum in Parkinson’s Disease (PD). The varied effects
of microglia in AD and PD depending on their stimuli
e.g. Aβ [1-3], NFT [2,4], neuromelanin [5,6] and α-syn
[7], indicate a multi-faceted role, both neurotoxic and
neuroprotective [8,9], but it is still uncertain if they play
a key role in the pathogenesis of AD [10] and PD
[11,12]. It is still unknown as to whether they are initia-
tors of the disease process, mediators of disease progres-
sion or a mixture of the two [13].. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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homeostasis of the CNS, e.g. providing trophic support to
neurons, antigen presentation and synaptic stripping [14].
Much like their peripheral macrophage counterparts, they
also act as a first line of defense against infection, and are
capable of destroying pathogens by triggering a pro-
inflammatory state via the so-called “classical” activation
pathway. While vital in protecting the tissue against for-
eign invasion, a consequence of classical activation can be
bystander damage to the surrounding neurons, by releas-
ing pro-inflammatory cytokines and reactive oxygen spe-
cies. Although these cytokines are essential for normal
functioning and are supportive of cell survival at low
levels, chronic and unregulated secretion will ultimately
lead to neuronal death [15]. These microglia are able to
change their phenotype [16], reverting to a tissue repairing
and wound healing role. This is known as the anti-
inflammatory phase, whereby the microglia assume an al-
ternative activated and/or acquired deactivation state [17].
In an ideal situation, this would spell the end of an infec-
tion episode and the restoration of normal functions.
However in the case of a chronic illness like AD, the evi-
dence suggests that there are microglia in both classical
and alternative activated states [18,19]. In the central ner-
vous system, an extremely vulnerable environment that
has limited capacity for regeneration, persistent activation
of microglia can bring about irreversible injury to the sur-
rounding tissue.
A variety of phenotypic markers have been used to iden-
tify both classical activation e.g. TNFα, IL-1α and ß, IL-6,
nitric oxide synthase and alternative activation states e.g.
IL-4, IL10, IL13 and TGFß in AD [18,20,21]. The ways in
which alternative activation may contribute to Parkinsonian
neuropathogenesis remains obscure. Moreover, possibleFigure 1 Schematic representation of the structure and domain organ
amino acid extracellular portion with 9 class B scavenger receptor cysteine
acid linker. This linker is composed of many proline, serine and threonine r
transmembrane segment, which is made up of 24 amino acids. The intrace
contain consensus sequences for phosphorylation and internalization.pathogenic functions of these macrophage and microglial
markers, including their stimuli for increased expression
and their effects remain to be determined. Whether they
are beneficial or detrimental to the viability of the neurons,
cannot be assumed by virtue of their classification states.
For example, pro-inflammatory cytokines might be associ-
ated with cytotoxicity, loss of ability to phagocytose Aβ pla-
ques e.g. via downregulation of Aβ receptors [22] and
neuronal degeneration, but TNF-α is protective due to its
pre-conditioning effect on metabolic excitotoxicity, Aβ tox-
icity and ischaemia [23]. Alternatively, anti-inflammatory
cytokines like TGF-ß are associated with alternative activa-
tion and hence are viewed as a form of immunosuppression
over aberrant cytotoxicity. However its presence might also
indicate the ongoing process of synaptic stripping [24].
Phagocytosis, as one of the key processes associated with
alternative activation, is crucial for clearance of Aβ pla-
ques. It has been reported that brain and blood-derived
macrophages play an important role in facilitating the
drainage of waste products from the brain, and are able to
clear Aβ plaques much more efficiently than resident
brain microglia [25-28]. However this is not known to take
place efficiently in AD brains, with Aβ plaques and cere-
bral amyloid angiopathy [29,30] standing testament to this
fact. CD163 (Figure 1) is a phagocytic marker, of which ex-
pression is thought to be exclusive to perivascular (PVM)
and meningeal macrophages [31-34]. It is a glycoprotein
belonging to class B of the scavenger receptor cysteine
rich superfamily. It functions as a membrane bound scav-
enger receptor for clearing extracellular haptoglobin-
hemoglobin (Hp-Hb) complexes [35]. It is also able to
recognize and bind Gram-negative and Gram-positive
bacteria, and may have a role to play in host defense [36].
It has an immunoregulatory function, and is associatedization of membrane-bound CD163. CD163 consists of a 1003
-rich (SRCR) domains, with domains 6 and 7 separated by a 31 amino
esidues (PST). Another PST linker connects the last SRCR domain to the
llular cytoplasmic domain ranges from 49 to 89 amino acids that
Table 1 Age, gender and causes of death for AD cases
Alzheimer’s disease cases (Braak stages 5 or 6)
Case no. Age at death Gender Cause of death
1 65 F Pneumonia
2 65 M Pneumonia
3 65 F Pulmonary embolism
4 67 F Intracerebral haemorrhage
5 69 F Pneumonia
6 70 F Other heart disease
classified elsewhere
7 71 F Pulmonary embolism
8 71 F Pneumonia
9 71 F Pneumonia
10 71 M Pneumonia
11 72 F Pneumonia
12 74 M Pneumonia
13 74 F Pneumonia
14 75 F Pneumonia
15 76 M Pneumonia
16 76 F Pneumonia
17 76 F Pneumonia
18 77 M Pneumonia
19 77 M Pneumonia
20 78 F Malignant neoplasm of
bronchus and lung
21 79 M Intracranial injury
22 79 F Pneumonia
23 80 F Peritonitis
24 81 F Acute myocardial infarction
25 82 F Heart failure
26 83 M Pneumonia
27 85 F Heart failure
28 85 M Pneumonia
29 87 M Pneumonia
30 88 F Pneumonia
31 88 F Pneumonia
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tive activation of macrophages. This marker has been
studied in diseases with a prominent inflammatory com-
ponent, including HIV encephalitis, SIV encephalitis, mul-
tiple sclerosis and head injury. However, it has yet to be
fully characterized in AD and PD tissue, where there is
prolific glial activation.
Methods
Case selection and neuropathological assessment
Cases diagnosed with dementia were obtained from the
Corsellis archival collection. Alzheimer’s disease status
was determined by assessing AT8 staining based on the
protocol from BrainNet Europe Consortium (BNE) [37],
and staining for Aß plaques with 4G8. Those with Braak
stages 5/6 were chosen for this study. 7 μm sections from
formalin-fixed, paraffin-embedded tissue blocks of hippo-
campus, frontal cortex and occipital cortex were obtained
from each case. A total of 31 AD cases were used- 21 fe-
males and 10 males, age range 65–88, mean age at death
76 (Table 1).
PD, Parkinson’s disease with dementia (PDD) and de-
mentia with Lewy bodies (DLB) cases were obtained from
the Parkinson’s UK Tissue Bank at Imperial College
London. They were diagnosed clinically using data com-
piled retrospectively by one of us (RP). Presence of PD was
determined by two or more of the cardinal signs- rigidity,
bradykinesia, resting tremor and postural instability. Devel-
opment of dementia one year after onset of motor signs
were classified as PDD, while DLB cases developed cogni-
tive impairment within one year of, or preceding motor
signs. Cases were further confirmed neuropathologically for
α-synucleinopathy. Using BNE’s staging protocol for α-
synuclein pathology [38,39], 10 cases from Braak stage 6, 6
cases each from stages 4 and 5, and 5 cases from stage 3
were used in this study. The frontal cortex, cingulate cortex,
striatum, nucleus basalis of Meynert (NBM), hippocampus,
midbrain, pons, and medulla were obtained from each case.
The age at death, gender, and cause of death for PD, PDD
and DLB cases are listed in Table 2.
16 cases with no neurological or systemic disease were
also selected as controls. These were obtained from the
Corsellis archival collection and were sampled in the
same regions as AD cases (Table 3). There were no sig-
nificant differences in age at death between the AD, PD
and control group (p = 0.001).
Immunohistochemistry
Antibodies used are listed in Table 4. Sections were
treated in xylene, rehydrated and blocked in 0.3% H2O2.
After pretreatment slides were incubated at 4°C over-
night with primary antibody diluted in PBS; Supersensi-
tive Polymer-HRP kit (Biogenex) was then applied,
using 3–3 diaminobenzidine (DAB) for visualizationand haematoxylin for counterstaining. Slides were then
dehydrated and brought through xylene again before
mounting with DPX. Negative controls were carried out
with omission of primary antibody.
Immunofluorescence
Sections were treated in xylene, rehydrated and blocked in
0.3% H2O2. Slides were incubated at 4°C overnight with a
mixture of primary antibodies blocked with normal horse/
goat serum; then 1 hour in corresponding Alexa Fluor
Table 2 Age, gender, causes of death and BNE α-synuclein
staging for cases with PD
Parkinson’s disease (without dementia)
Case
no.
Age at
death
Gender α-syn
staging
(Braak)
Cause of death
1 75 F 4 -
2 81 M 4 Thrombosis histology
3 80 F 4 “Old age” and Parkinson’s disease
4 87 F 4 Gastrointestinal bleeding
5 49 M 5 -
6 75 M 5 Myocardial infarction, acute
renal failure, pneumonia
7 72 M 4 Cardio-respiratory arrest;
aspiration pneumonia,
Parkinson’s disease
8 77 F 5 End stage cardiac failure;
moderate to severe LV dysfunction;
Aortic & mitral valve disease;
colonic bleed, UTI
9 79 M 5 Bronchopneumonia,
Parkinson’s disease & GI bleed
10 66 M 4 -
11 86 M 6 Aspiration pneumonia and
small bowel obstruction
12 96 F 3 -
13 74 M 6 Bronchopneumonia
14 73 F 3 Progressive PD and
recurrent CVA
15 89 M 3 -
16 57 M 5 Gastric cancer, liver
and bone metastases
Parkinson’s Disease with Dementia (PDD)
1 61 M 6 Bronchopneumonia
2 80 F 6 Hypostatic pneumonia X 1 week;
Parkinson’s disease;
senile/presenile Dementia
3 72 M 6 -
4 66 M 6 Chest infection
5 80 M 3 Dementia in Parkinson’s disease:
Lewy body dementia
6 84 F 6 -
7 78 F 6 Sepsis, pneumonia
Dementia with Lewy Bodies (DLB)
1 70 M 5 Bronchopneumonia
2 61 M 3 Fall; upper cervical
spinal cord damage
3 69 M 6 Dementia with Lewy bodies
4 74 M 6 -
Table 3 Age, gender and causes of death for control cases
Control cases
Case no. Age at
death
Gender Cause of death
1 59 M Polyarteritis nodosa and
related conditions
2 59 F Gastric ulcer
3 62 M Acute myocardial infarction
4 63 M Seropositive rheumatoid arthritis
5 63 F Chronic renal failure
6 68 F Crushing injury of thorax and traumatic
amputation of part of thorax
7 69 F Acute myocardial infarction
8 71 M Chronic tubulo-interstitial nephritis
9 71 M Haemopericardium, ruptured
acute myocardial infarction
10 72 F Peptic ulcer
11 74 M Acute myocardial infarction
12 75 M Squamous cell carcinoma of the lung
13 76 F Pulmonary embolism
14 78 M Acute myocardial infarction
15 80 F Breast carcinoma with spinal
metastasis; carcinosarcoma uterus
16 81 F Bronchial pneumonia, old age
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gen). Fluorescent sections were mounted with ProLong
Gold Anti-fade reagent with DAPI (Invitrogen).Double immunofluorescence (IF) was carried out with
rabbit polyclonals α-syn, Aβ, tau, MRC1 and Iba1 to-
gether with mouse monoclonal CD163.
Semi-quantitative assessment of CD163 positive microglia
For each brain region, the area with the highest amount
of CD163 immunoreactive parenchymal microglia was
determined by eye and examined at x10 magnification
with a field area of 0.153 mm2. Image Pro Plus software
was then used to assess the percentage area (%area) oc-
cupied by the parenchymal microglia (stained brown
with DAB). In order to prevent CD163 immunoreactive
PVM from influencing the measurement of CD163 im-
munoreactive microglial cells in the parenchyma, all
PVM were manually deselected from images. Intra-rater
reliability was examined by measuring the %area across
20 samples on four occasions in a span of two weeks.
Samples were presented in a random order and the
process was performed blinded to previous values.
Cronbach’s alpha value was found to be 0.973, indicat-
ing high internal consistency during assessment.Statistical analysis
Statistical analysis was performed using SPSS version
20. Shapiro-Wilk test was used to assess normality for
all comparisons. Mann–Whitney U test was used to
Table 4 Antibodies, their clones, epitopes, pretreatments and dilutions used
Clone/type Epitope (Immunogen) Pre-treatment Dilution Source
Alpha-synuclein 42, Mouse IgG1 Rat aSN15-123 80% Formic acid
for 1 hour
1:1000 Becton-Dickinson
Alpha-synuclein Rabbit polyclonal a.a. 111-131 80% Formic acid
for 10 mins
1:2000 Millipore
Tau AT8, mouse IgG1 Tau phosphorylated at Ser-202/Thr-205 None 1:800 Autogen bioclear
Tau Rabbit Polyclonal C terminal a.a. 243-441 None 1:800 Dako
Abeta 4G8, IgG2b a.a. 17-24 80% FA for 1 hour 1:2000 Signet
Abeta Rabbit polyclonal Synthetic peptide corresponding to a.a.
1–16 of Abeta peptides 38, 40, and 42
80% FA for 1 hour 1:500 Synaptic systems
MRC1 Rabbit polyclonal Macrophage mannose receptor 1 precursor
recombinant protein epitope signature tag
Microwave in 10 mM citrate
buffer pH 6 for 20 mins
1:1000 Prestige antibodies
Iba1 Rabbit polyclonal Synthetic peptide corresponding
to C-terminus of Iba1
Microwave in 10 mM citrate
buffer pH 6 for 20 mins
1:400 Wako
CD68 PG-M1, IgG3 Fixative-resistant epitope on
macrophage-restricted form of CD68
Microwave in 10 mM citrate
buffer pH 6 for 20 mins
1:500 Dako
CD163 10D6, IgG1 Prokaryotic recombinant protein
corresponding to domains 1–4 of
N-terminal region of CD163
Microwave in 10 mM citrate
buffer pH 6 for 20 mins
1:50 Novocastra
Fibrinogen Rabbit polyclonal Fibrinogen isolated from human plasma Microwave in 10 mM citrate
buffer pH 6 for 20 mins
1:5000 Dako
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control cases. Differences in the %area occupied by
CD163 immunoreactive microglia between AD, PD,
PDD and controls were tested using Kruskal-Wallis
test, followed by post hoc Dunn-Bonferroni’s test for
correction of multiple comparisons, or Mann–Whitney
U test. Comparison across different brain regions
within each disease was done using Friedman’s two-
way ANOVA, followed by post hoc Dunn-Bonferroni’s
adjustment. Spearman and partial correlations were
used to detect the relationship between age of onset,Figure 2 Immunohistochemical detection of CD163. (a-c) a- PVM immu
b- Parenchymal microglia immunoreactive for CD163 in the occipital corte
to meningeal spaces in the occipital lobe of an AD case. (d-f) Range of CD
e-moderate, to f-severe.age at death, disease duration with %area of CD163 im-
munoreactivity. The criteria for statistical significance
was set at p < 0.05.
Results
CD163 immunoreactivity is restricted to PVM in majority
of control cases
In 12 out of 16 control cases, the only CD163 positivity
seen was in PVM, as flattened, elongated cells adjacent to
vessel walls (Figure 2a), as well as macrophages in the
meninges and choroid plexus. Little or no CD163noreactive for CD163 in the frontal cortex of a control case.
x of an AD case. c- CD163 immunoreactive microglia in close proximity
163 immunoreactivity (based on %area) in microglia from d-mild,
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This observation is in agreement with the concept that
CD163 is a marker specific for monocytes [31,33,40].
PVM and parenchymal microglia are CD163
immunopositive in AD and PD
All cases of AD and PD exhibited CD163 immunoreactive
microglia in the parenchyma. This finding is different from
other reports [41] of CD163 immunoreactive microglia
mostly restricted to perivascular and sub-arachnoid spaces
rather than inclusion of parenchymal microglia; perhaps
due to examination of relatively few cases. The parenchy-
mal microglia in our patients were typically ramified inTable 5 CD163 %area assessment in AD cases
AD
cases
Frontal
cortex
Occipital
cortex CA1 CA2
1 0.925 1.126 - -
2 2.946 1.466 0.548 0.238
3 1.049 8.015 - -
4 8.562 6.429 3.128 1.154
5 5.107 3.245 0.701 0
6 4.068 1.624 0.663 0.384
7 3.279 1.243 0 0
8 1.143 1.8 0.204 0.055
9 0.7 1.911 0.749 0.659
10 1.135 1.439 0.557 0.254
11 3.538 1.308 - -
12 1.227 1.331 0.318 0
13 2.575 3.488 - -
14 2.771 2.071 1.741 0.205
15 0.692 1.141 1.891 0
16 2.623 5.077 - -
17 0.55 0.231 0.094 0
18 1.021 1.676 0.455 0
19 2.711 1.68 - -
20 4.037 4.048 1.265 0.459
21 0.38 0.176 0.203 0.294
22 0.437 0.184 0.242 0
23 1.893 1.602 0.094 0
24 1.192 1.056 - -
25 1.323 2.143 0.674 0.129
26 0.866 1.911 - -
27 0.406 0.973 - -
28 0.177 0.355 - -
29 0.067 0.374 0 2.231
30 1.615 2.099 0.658 0.437
31 0.943 2.03 0.192 0appearance with shorter, thicker processes (Figure 2b),
were distributed in a patchy pattern, and tended to be
close to the meninges (Figure 2c). CD163 immunoreactiv-
ity was evident in both AD and PD cases, ranging from
mild to severe (Figure 2d-f).
CD163 immunoreactivity is more extensive in AD than in
PD cases
There were significantly more CD163 immunoreactive
microglia in the brains of Alzheimer patients; frontal cor-
tex (Mann Whitney U = 105.00, p < 0.001), CA1 (U =
135.00, p < 0.005), CA3 (U = 190.50, p < 0.05), CA4 (U =
177.00, p < 0.05), subiculum (U = 94.00, p < 0.001) andHippocampus
CA3 CA4 Subiculum Entorhinal cortex
- - - -
0 0.22 0.181 0
- - - -
0.863 2.978 3.128 3.433
0.288 1.085 2.478 4.93
0 0.06 0.052 0.063
0.011 0.032 0.512 0.115
0 0.054 0.095 0.376
0.167 0.715 1.565 2.384
0.455 0.497 2.203 2.194
- - - -
0.089 0.207 1.041 4.186
- - - -
0.187 0.11 1.47 1.479
0.456 0.191 1.335 0.43
- - - -
0 0 0.042 0
0.198 0.256 0.528 0.808
- - - -
0.309 0.433 1.181 0.719
0.337 0.247 1.634 0.3
0 0.388 0.194 0.67
0.151 0.158 0.206 2.133
- - - -
0.257 0.73 1.075 0.573
- - - -
- - - -
- - - -
0 0 0.305 2.238
0.38 0.421 1.025 2.219
0 0.217 0.588 0.156
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those from Parkinson patients. (refer to Tables 5 and 6 for
semi-quantitative measurements) Similarly, in AD com-
pared to PD, PVM were more numerous and expressed el-
evated levels of CD163 (Figure 3).
The %area of CD163 immunoreactivity in parenchy-
mal microglia was compared within the available brain
regions for each disease type using Friedman ANOVA
and brain regions and the areas of highest CD163 load
were noted. The frontal and occipital cortex of AD cases
had the highest and second-highest %area occupied by
CD163 immunoreactive microglia, respectively (p <
0.001), while in PD cases the substantia nigra (SN) and
dorsal motor nucleus of the vagus nerve (DMV) had the
highest and second-highest %area occupied by CD163
immunoreactive microglia, respectively (p < 0.001). There
was no difference between PD without dementia and PDD
in any of the brain regions tested.Table 6 CD163 %area assessment in PD cases
PD
cases
Frontal
cortex
Cingulate
cortex
Caudate
nucleus
Internal
capsule
Putamen NBM
CA1
1 0.02 0.04 0.09 0.04 0.24 0 0
2 0.21 0.09 0.08 1.41 0.16 0.38 0.08
3 0.1 0.05 0.13 0.04 0.08 0.23 0
4 0 0 0 0 0.05 0.34 1.82
5 0 0 0 0 0 0 0
6 0.19 1.06 0.18 3.65 2.31 1.26 0.93
7 0.19 0 0 0 0 0.17 0
8 0.07 0 0 0 0.67 0.16 0
9 1.55 0.37 0 1.07 1.55 0.23 0.81
10 0 0 0 0 0 0.12 0
11 0 0 0 0 0 1.9 0
12 1.2 1.8 0.27 0.95 0.49 2.48 0.71
13 0.27 0 0 0 0 0.04 0
14 0.42 1.26 1.65 2.8 3.87 0.41 0.84
15 0.47 0.14 0 0.65 0 0.57 0.18
16 0.28 0.8 0.54 0.27 0.13 0.38 0
17 0 0 0 0 0.04 0.5 0
18 0.06 0 0.37 0 0.8 0.28 0
19 0.08 0 0 0 0 - 0
20 0.03 0.08 0 0 0 0 0
21 0.21 0.39 0 0 0 0 0
22 0.65 0.37 0.26 0.12 0.11 0.34 0.19
23 1.83 1.41 0.57 2.26 1.08 1.87 -
24 0.05 0.1 0 0 0 0 0
25 0.27 0 0.08 0.5 0.25 0.4 0
26 0.13 0.22 0.21 0 0.14 - 0.62
27 1.41 0.4 0.2 0.32 0.13 0.19 0.54Do CD163 immunoreactive parenchymal microglia
originate from the periphery?
Double immunofluorescence labeling with Iba1 and
MRC1 antibodies was to explore the similarities be-
tween CD163 immunoreactive microglia and PVM. Iba1
is a pan-microglia marker that does not label PVM,
while MRC1 is a PVM specific marker. Association with
either Iba1 or MRC1 may shed light on whether the
CD163 immunoreactive microglia originated from the
periphery, or are resident to the CNS. Fibrinogen was
also used to test for damage to the integrity of the blood
brain barrier (BBB).
While it was expected that all CD163 immunoreactive
microglia would co-stain with Iba1, absence of Iba1 was
observed in many of them. (Figure 4a & b) It was found
that MRC1 positivity was strictly limited to PVM, with no
staining seen in microglia (Figure 4c). Staining for fibrino-
gen revealed perivascular leakage around small to mediumHippocampus SN LC DMV
CA2 CA3 CA4 Subiculum Entorhinal cortex
0 0 0.34 0 0.02 0.52 1.07 0.61
0 0.01 0.09 0 1.09 1.09 0.14 1.43
0 0 0 0.03 0.3 0.84 0.49 0.9
0 0 0 0 0.2 0.78 0.2 0.53
0 0 0 0 0 0.11 0.1 0.06
0 0 0.05 0.32 1.03 0.76 0.91 2.78
0.16 0 0.04 0 0.12 0.45 0.24 0.42
0 0 0 0 0.26 0.46 0.14 0.28
0.34 0.56 0.2 1.57 0.53 1.57 0.19 0.16
0 0 0 0 0 0 0.07 0
0.24 0.12 0.33 0 0 0.12 - 0
0.63 1.14 1.57 0.89 1.43 1.86 3.86 2.31
0 0.02 0.1 0.12 0 0.58 0.44 1.5
0.49 0 0.09 0.41 0.67 2.27 1.84 3.69
0.03 0.07 0.69 0.26 0.22 1.87 0 1.04
0 0 0.1 0 0 1.27 0.46 0.08
0 0 0.06 0.05 0 0.32 0.13 0.21
0 0 0 0 0.17 1.43 0.23 0.27
0.38 0 0.02 0 0.35 0.87 0.76 2.81
0 0 0 0.05 0.62 0.63 0.17 0.22
0 0 0.12 0 0.06 0.22 0.63 0.7
0.56 0.02 0.27 0.23 0.17 0.21 0.52 0.68
- - - - - 2.83 2.76 1.12
0 0 0 0 0.06 0 0.26 0.14
0 0 0 0.04 0.07 0.65 0.42 0.44
0.26 0.32 0.28 2.8 0.65 0.87 0 0.29
1.94 0.4 0.71 1.32 0.5 1.55 0.11 0
Figure 3 Comparison of percentage area of CD163 immunoreactive microglia in various brain regions of AD and PD cases. %area of
CD163 immunoreactive microglia was assessed in all available brain regions in 31 AD cases and 27 PD cases. Significant differences were
observed from comparison of the median between the frontal lobe and hippocampal regions (CA1, CA3, CA4, subiculum and entorhinal cortex)
of AD and PD cases. Columns represent mean %area of CD163 immunoreactive microglia in their respective brain regions for AD and PD cases.
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cases. (Figure 5a & b) This was seen as a diffuse pattern
that remained in a halo around the compromised vessels.
Most vessels in both AD and PD were spared from BBB
breakdown, as surmised from the presence of fibrinogen
only within the blood vessel lumen. Double immunofluor-
escence showed CD163 immunoreactive microglia had
a tendency to be found in close proximity to sites of
BBB damage. (Figure 5c & d) These blood vessels with fi-
brinogen leakage were not associated with CAA, neither
did CAA show any association with CD163 immunoreac-
tive microglia.
CD163 immunoreactive microglia are associated with Aβ
plaques, but not NFT or α-syn pathology
CD163 immunoreactive microglia were closely associated
with Aβ plaques, as shown with double staining. The
number of plaques associated with these microglia was de-
pendant on the amount of CD163 immunoreactivity of
microglia within the same vicinity. As such, a variety of
scenes were observed, including the association of the
microglia with most Aβ plaques (in cases with numerous
CD163 immunoreactive microglia); Aβ plaques not associ-
ated with any of the microglia (in cases with little or no
CD163 immunoreactive microglia), and CD163 immuno-
reactive microglia not associated with any Aβ plaques. All
AD cases analysed had extensive Aβ plaque deposition
while the number of CD163 immunoreactive microgliavaried drastically, hence no consistent relationship be-
tween these microglia and the number of Aβ plaques was
observed.
Microglia clusters were seen within plaques with most
of them found in the core of neuritic plaques, while fewer
of them were within diffuse plaques. (Figure 6a) While
plaque-associated microglia retained their ramifications,
some appeared to be of a more amoeboid shape, indicat-
ing phagocytosis. This was observed in AD, PD, and con-
trol cases.
To assess the potential of neuron-associated CD163
immunoreactive microglia, double immunofluores-
cence was performed using antibodies to CD163 and
either hyperphosphorylated tau-containing neurofibril-
lary tangles or α-syn. There was no visible sign of
interaction between CD163 immunoreactive microglia
and intracellular NFT (Figure 6c) or α-syn. However,
in rare cases, microglia were found adjacent to extra-
cellular α-syn (Figure 6b). Double immunofluorescence
was also performed with CD68 and CD163, to confirm
the phagocytic nature of CD163 immunoreactive
microglia. Many of the CD163 immunoreactive micro-
glia were also positive for CD68, particularly those with
a more amoeboid shape (Figure 6d).
Discussion
CD163 is generally considered to be a specific PVM marker
[31,40], and indeed in our study of brains from
Figure 4 Double immunofluorescence of CD163 with microglia/macrophage markers Iba1 and MRC1. (a and b) Double
immunofluorescence for CD163 (red) and Iba1 (green) in the occipital cortex of AD cases. Not all CD163 immunoreactive microglia stained for
Iba1 (arrows), a marker highly specific for microglia. This suggests that CD163 immunoreactive parenchyma microglia might originate from
systemic cells that have yet to obtain an Iba1 immunoreactive profile. The presence of microglia immunoreactive for both Iba1 and CD163 also
indicate that resident microglia might be able to upregulate CD163 with stimulation from the periphery. (c) Double immunofluorescence for
CD163 (red) and MRC1 (green) in the occipital cortex of an AD case. CD163 co-stains PVM with MRC1. MRC1 immunoreactivity is limited to PVM
(circled). This is in concordance with findings that MRC1 is restricted to PVM despite a clear BBB breakdown.
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stricted to such macrophages. However, this was not the
case in our study of AD and PD, where in addition to an in-
tense staining of PVM, CD163 was also expressed by acti-
vated microglial in the parenchyma. Foamy macrophages
and microglia in the brain parenchyma have previously
been found to express CD163 in HIV-encephalitis [41],
multiple sclerosis, and head injury tissue [42]. In concord-
ance with the general consensus, these are inflammatory
disorders, and the observation can be attributed to break-
down of the BBB and infiltration of peripheral monocytes
[31,33,40]. Therefore the reason for significant increases
of CD163 immunoreactive parenchymal microglia in AD
could be an immune response specific to the neuropathol-
ogy of AD [1,19]. Although to a lesser degree, we also ob-
served CD163 immunoreactive microglia in PD, but boththe numbers of immunoreactive microglia and intensity of
their immunoreactivity were less than that in AD. CD163
immunoreactive microglia were most prominent in the
brainstem of PD cases, coinciding with the regions af-
fected in the earlier stages of the disease. While some of
the CD163 immunoreactive microglia coincided with pla-
ques both in AD and PD, focal aggregations of such cells
were also seen in the absence of plaques. There was no
correlation between the number of Aβ plaques and the
number of CD163 immunoreactive microglia across the
cases. Such an observation might suggest that these
microglia are reacting both to neuronal debris and extra-
cellular abnormal aggregates of protein, including Aβ and
occasional Lewy bodies. The reason for CD163 expression
in the parenchymal microglia of AD and PD patients can-
not be solely attributed to Aβ plaques.
Figure 5 Double immunofluorescence of CD163 with fibrinogen. (a and b) Immunofluorescence for fibrinogen in the (a) occipital cortex of
an AD case and (b) cingulate cortex of a PD case. Fibrinogen was found to exude from compromised blood vessels in both AD and PD cases,
but to a lesser extent in the PD cases. Arrows point to compromised blood vessels where fibrinogen has leaked into the surrounding
parenchyma. (c and d) Double immunofluorescence for CD163 (red) and fibrinogen (green) in the (c) frontal and (d) occipital cortex of AD cases.
Presence of CD163 immunoreactive microglia at close proximity to areas of fibrinogen leakage in the parenchyma. This raises the possibility that
CD163 immunoreactive microglia are a result of migration from the periphery. Astrocytes were also found to have fibrinogen immunoreactivity.
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with numerous sources from postmortem tissue in humans
and transgenic animals to in vitro cell cultures providing
evidence that Aβ plaques stimulate pro-inflammatory reac-
tions [19,34,36,43,44]. Classically activated microglia are
plentiful and widespread throughout the brain in PD and
such activation has been linked to the destruction of dopa-
minergic neurons in the SN and striatum [12,45,46]. Re-
cently, the alternative activation state of microglia in AD
has garnered attention. Colton et al. demonstrated the
presence of mRNAs of alternative activation genes in
postmortem specimens and cell cultures and transgenic
mice models, although Walker et al. 2009 [47] did not
detect the mRNA of IL-4 and IL-13 in most of the brainsamples examined. Most importantly, microglia have been
shown to be capable of phagocytosis through immunization
with Aβ42 peptides in the Elan clinical trials. In these pa-
tients, microglia were found to increase their expression of
CD68 and phagocytosed Aβ was found within lysosomes
[48].
CD163 is a marker for acquired deactivation and phago-
cytosis [16,20]. Its expression is induced/enhanced by
interleukins (IL)- 6, IL-10, macrophage colony stimulating
factor (M-CSF), and glucocorticoids [49-52]. The pro-
moter region of CD163/HbSR gene contains potential
binding sites for glucocorticoid receptor and transcription
factors for myeloid differentiation [53]. Production of
IL-6 and IL-10 actually occurs simultaneously with
Figure 6 Double immunofluorescence detection of CD163 with Aβ, α-syn and CD68. (a) Double immunofluorescence for CD163 (red) and
Aβ (green) in the occipital cortex of an AD case. CD163 immunoreactive microglia clusters around dense cored plaques. (b) Double
immunofluorescence for CD163 (red) and α-syn (green) in the frontal cortex of a PD case. CD163 immunoreactive microglia cluster around
extracellular LBs. Most of the LBs were intracellular and did not coincide with CD163 immunoreactive microglia. It is predictable that these
microglia would react with abnormal aggregates of protein found extracellularly, instead of intracellular pathology. (c) Double immunofluorescence for
CD163 (red) and tau (green) in the hippocampus of an AD case. CD163 immunoreactive microglia are in close proximity with neuropil thread but with
no specific associations. (d) Double immunofluorescence for CD163 (red) and CD68 (green) in the frontal cortex of an AD case. CD68 is a marker for
lysosomes; association (arrow) indicates possible phagocytic properties of CD163 immunoreactive microglia, reinforcing its role as a scavenger receptor.
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boosting CD163 expression [54]. Though touted as an
anti-inflammatory marker, it is not induced by IL-4 or
IL-13. It is downregulated by lipopolysaccharide (LPS),
TNF-α, TGFβ and IFN-γ [55-57].Much interest has been shown in Aβ and its removal
from the brain via natural methods or vaccination [58];
CD163 immunoreactive microglia clusters around Aβ
plaques support the idea that they might serve a similar
purpose. As seen in our study, CD163 immunoreactive
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bodies, only extracellular Lewy bodies- further support-
ing a role in phagocytosis. In spite of this, most of them
remain in a ramified state, albeit with shortened and
thickened processes, which raises doubt with regards to
phagocytic function. One possibility might be that they
are influenced by the chronic state of the disease and
the persistent generation of Aβ plaques (in AD) [22].
Staining with MRC1 remains restricted to the perivas-
cular spaces in AD and PD. MRC1 is a mannose recep-
tor involved in adhesion, pathogen recognition and
clearance, and a marker for PVM [59]. This is similar
to other findings that no other MRC1 expression was
found in the parenchyma, despite acknowledged BBB
damage e.g. in multiple sclerosis; and also in excito-
toxic damage, acute inflammation and other chronic
neurodegeneration models [31,59]. It demonstrates that
although they might serve similar phagocytic functions,
CD163 and MRC1 expression and consequently their
targets might be different e.g. MRC1 is involved in the
recognition and endocytosis of foreign pathogens
[59,60]. It also indicates that blood-derived macro-
phages can adjust quickly to the CNS environment.
There has been doubt as to whether the BBB is intact
in AD [19,61]. In this study most of the microglia were
found near the meninges, which might indicate infiltra-
tion of PVM from the periphery. Furthermore, some of
these microglia were found to coincide with leakage of
fibrinogen around vessel walls, an indication that there
is a breakdown in BBB. Migration of CD163 immunore-
active macrophages from the periphery into the paren-
chyma might stem from compromise in the vasculature.
This also corresponds with the observation that many of
the CD163 immunoreactive microglia were not immu-
nopositive for Iba1. Iba1 is a calcium binding protein
expressed in macrophages/microglia [62,63], which labels
all microglia and only certain types of PVM [29,64-66].
Signaling or infiltration through the BBB could strengthen
the idea that systemic inflammation plays a part in the
pathology of AD and PD [67-69], and might explain the
variations in amount of CD163 positivity within each dis-
ease. Presence of microglia double immunoreactive for
Iba1 and CD163 can be explained by the capability of resi-
dent parenchymal microglia to upregulate CD163, induced
by signaling from the periphery. Vascular risk factors that
are associated with an increased chance of developing AD
might result in either an infiltration of peripheral macro-
phages into the brain, or increased signaling through the
BBB to cause an abnormality in protein expression and up-
regulation. With regards to histological techniques, there
has been no marker singularly capable of distinguishing be-
tween blood derived macrophages and resident brain
microglia. If these CD163 immunoreactive microglia are in-
deed derived from the blood, it would be interesting tofurther confirm their origins using markers specific for sys-
temic macrophages. Animal models can also be used to
track CD163 immunoreactive peripheral macrophages and
their probable entry into the brain parenchyma with or
without a breach of the BBB. More experiments can be
done to delve deeper into the presence and function of
CD163 in AD and PD, and the subset of microglia/macro-
phages that express CD163 in these diseases.
Conclusions
In this novel study we have shown CD163 immunoposi-
tivity in parenchymal ramified microglia in all the AD
and PD cases we tested. Many were found clustered
around neuritic plaques; apposition with CD68 indicates
the possibility for phagocytic function, and that Aβ is a
stimulant for microglia. Further investigation is needed
into the molecular interactions between CD163 and
amyloid plaques, and whether these microglia co-express
other receptors for Aβ. Amyloid plaques do not neces-
sarily associate with CD163 immunoreactive microglia
and vice versa, suggesting that the real reason for upreg-
ulation of CD163 by microglia is not a response to in-
creased Aβ deposition. They were also found at a higher
density around compromised blood vessels. AD had a
much more florid reaction compared to PD, suggesting
either a reaction specifically towards AD related path-
ology, or a more apparent BBB breakdown in AD than
PD. Our study is the first to make a large-scale investiga-
tion on the expression of CD163 in AD and PD. Increase
in CD163 immunoreactivity in AD was more significant
than in PD, and this might be attributed to a more obvi-
ous vascular breakdown in AD, as well as the tendency
for CD163 immunoreactive microglia to react with
extracellular protein pathology.
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